Boston Scientific (BSX) Earnings Date & Reports

Key Takeaways

• Boston Scientific (BSX) is scheduled to report third-quarter 2026 results on Wednesday, October 28, 2026, before the market opens.
• Management has guided to adjusted earnings per share (EPS) of $0.80 to $0.82, with reported and organic net sales growth of roughly 3% to 5%.
• Consensus estimates sit slightly above the company's guidance, with analysts modeling adjusted EPS near $0.83 and revenue of roughly $5.3 billion to $5.4 billion.
• Investors are focused on the WATCHMAN left atrial appendage closure franchise and the U.S. electrophysiology (EP) business, two areas where growth has recently slowed.
• The company has already lowered its full-year 2026 outlook and announced a restructuring program, making this quarter an important read on whether the reset is taking hold.

Earnings Context and Why It Matters

Boston Scientific enters its third-quarter 2026 report at an important inflection point. The company's second quarter delivered solid headline results — revenue of $5.44 billion and adjusted EPS of $0.86 — but management simultaneously trimmed its full-year guidance, citing a sharp, unexpected slowdown in the U.S. WATCHMAN market and intensifying competitive pressure in U.S. electrophysiology. That shift sent the stock lower and reset investor expectations. Because Boston Scientific has long been valued for above-market growth, this quarter's print will test whether the company's diversified portfolio and newer products can stabilize momentum in its two key franchises.

Earnings Expectations

For the third quarter of fiscal 2026, Boston Scientific has guided to adjusted EPS of $0.80 to $0.82 on net sales growth of approximately 3% to 5% on both a reported and organic basis. By comparison, the company earned adjusted EPS of $0.75 on revenue of $5.07 billion in the year-ago quarter, meaning the midpoint of guidance implies a mid-single-digit earnings increase and a revenue figure of roughly $5.2 billion to $5.3 billion.

Wall Street's consensus expectations sit modestly above management's outlook. Analysts are modeling adjusted EPS near $0.83 to $0.84, with revenue estimates clustered around $5.3 billion to $5.4 billion. That gap is notable: guidance issued alongside second-quarter results already fell short of Street forecasts, so another print below consensus could reignite questions about the durability of growth in WATCHMAN and EP. Investors will also watch segment-level detail, including MedSurg performance in endoscopy, urology, and neuromodulation, as well as operating margins, which reached an adjusted 28.4% in the prior quarter.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking medical-device names like Boston Scientific and its peers, the AI Screener offers a structured way to surface ideas and monitor shifting momentum across the sector.

Market Reaction and Investor Sentiment

Sentiment heading into the third-quarter report remains cautious. Boston Scientific shares have significantly underperformed the broader market over the past year, and the guidance reset in late July kept a lid on enthusiasm even after an EPS beat. The stock's reaction to prior reports has been mixed: a solid second quarter was undercut by lowered forward guidance, reinforcing the market's focus on the trajectory of WATCHMAN and electrophysiology rather than headline results alone. Heading into October, investors appear to be pricing in a slower-growth environment, which means the company's commentary on whether the second half is tracking in line with its revised assumptions — and any signs of stabilization or further deterioration — will likely matter more than the quarter's raw numbers.

Forward Outlook and Key Factors to Monitor

Beyond the third-quarter print, investors should watch how management frames the WATCHMAN and electrophysiology franchises. The company has acknowledged that U.S. WATCHMAN demand slowed sharply due to evolving clinical evidence and shifting referral patterns, while U.S. EP faces competitive share movement. Any update on whether those headwinds are stabilizing — or extending into 2027 — will be closely scrutinized.

A second focus is the restructuring program announced earlier this year, which targets roughly $500 million in annual run-rate savings exiting 2029. Details on the pace of charges, headcount actions, and margin impact will help investors assess how quickly cost discipline can offset slower revenue growth.

Finally, watch for updates on the company's product pipeline and growth catalysts, including the FARAPULSE pulsed field ablation system, the SEISMIQ coronary intravascular lithotripsy platform, and recent portfolio investments. These newer technologies are central to the case for a reacceleration in growth in 2028, and any clinical or commercial milestones around them could shape sentiment well beyond a single quarter.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations